Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its news flow reflects the progress of these programs. Company announcements highlight clinical data from trials of rondecabtagene autoleucel (ronde‑cel, also referred to as LYL314) in relapsed and/or refractory large B-cell lymphoma (LBCL), including reported overall response rates, complete response rates, durability of responses, and safety findings from Phase 1/2 and pivotal studies.
News updates frequently cover milestones in Lyell’s pivotal development of ronde‑cel, such as the initiation and conduct of the single‑arm PiNACLE trial in the third‑ or later‑line setting and the Phase 3 PiNACLE – H2H head‑to‑head trial in the second‑line setting against approved CD19 CAR T-cell therapies. These releases often include details on trial design, patient populations, endpoints, and presentations at major scientific meetings like the American Society of Hematology (ASH) and the International Conference on Malignant Lymphoma.
For solid tumors, Lyell’s news also reports on LYL273, a GCC‑targeted CAR T-cell product candidate in Phase 1 development for refractory metastatic colorectal cancer. Disclosures include response rates, disease control rates, safety observations, and regulatory designations such as Fast Track status from the U.S. FDA. Additional corporate news items describe licensing transactions, equity financings, and operational updates that support the advancement of Lyell’s pipeline and manufacturing capabilities.
Investors and observers following LYEL news can use this page to review company-issued press releases on clinical trial readouts, regulatory designations, scientific conference presentations, licensing agreements, and capital raises related to Lyell’s CAR T-cell programs in hematologic malignancies and solid tumors.
Lyell Immunopharma (Nasdaq: LYEL), a late-stage clinical company focused on next-generation CAR T-cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th at 9:15 AM ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 8:00 AM ET. Investors can access the live webcasts through Lyell's website, with replays available after the presentations.
Lyell Immunopharma (Nasdaq: LYEL) reported significant progress in Q2 2025, highlighted by positive clinical data for their lead program LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma. The Phase 1/2 trial showed impressive results with an 88% overall response rate and 72% complete response rate in 3L+ patients.
The company has initiated the PiNACLE pivotal trial for third-line or later treatment and plans to begin a second-line trial by early 2026. Additionally, Lyell secured a $100 million private placement, with an initial closing of $50 million. The company's pro-forma cash position of $347 million is expected to fund operations through mid-2027.
Q2 2025 financial results showed a net loss of $42.7 million, an improvement from $45.8 million in Q2 2024, with R&D expenses decreasing to $34.9 million from $40.3 million year-over-year.
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage CAR T-cell therapy company, has secured a private placement agreement worth up to $100 million with institutional and accredited investors. The deal includes an initial $50 million closing at $13.32 per share, expected on July 25, 2025, with potential for an additional $50 million tied to clinical milestones.
The financing includes flexible terms with milestone-based pricing ranging from $10.41 to $25.61 per share and investor call options at $30.73 per share. The proceeds will fund two pivotal-stage trials of LYL314, including the PiNACLE trial for large B-cell lymphoma, and extend the company's cash runway into mid-2027.
Lyell Immunopharma (Nasdaq: LYEL) announced its participation in the H.C. Wainwright "HCW@Home" Series on June 25, 2025. The virtual fireside chat will feature CEO Lynn Seely and CFO Charlie Newton discussing their lead product LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma (LBCL).
The presentation will highlight recent positive clinical data presented at ICML and focus on next-generation CAR T-cell therapies. LYL314, which has received both RMAT and Fast Track designations from the FDA, aims to improve complete response rates and response duration compared to existing CD19-targeted therapies.
Lyell Immunopharma (LYEL) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its LYL314 therapy, targeting relapsed/refractory large B-cell lymphoma. The designation was based on promising data from an ongoing Phase 1/2 trial.
Key clinical results include:
- 94% overall response rate (16/17 patients)
- 71% complete response rate (12/17 patients)
- 71% of patients maintaining response at last follow-up
- Median follow-up of 6.3 months
- No Grade 3+ cytokine release syndrome reported
LYL314 is a dual-targeting CD19/CD20 CAR T-cell therapy designed to improve complete response rates compared to existing treatments. The company plans to initiate two pivotal programs: one in mid-2025 for 3rd+ line treatment and another in early 2026 for 2nd line treatment. Additional clinical updates are expected throughout 2025.